Literature DB >> 23803674

Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role.

Maria Teresa Sartori1, Alessandro Della Puppa, Andrea Ballin, Elena Campello, Claudia Maria Radu, Graziella Saggiorato, Domenico d'Avella, Renato Scienza, Giuseppe Cella, Paolo Simioni.   

Abstract

Venous thromboembolism (VTE) may complicate the clinical course of glioblastoma multiforme (GBM). Circulating microparticles (MPs) have been associated with cancer-related VTE. Sixty-one consecutive patients with GBM undergoing gross-total (41) or subtotal (20) surgical resection followed by radio-chemotherapy were prospectively evaluated. MPs numbers according to cellular origin and the procoagulant activity of annexin V positive (AV+) MPs (MP-activity) were measured before surgery and then 1 week and 1, 4, and 7 months after surgery. Glial (GFAP+) and endothelial (CD62E+) derived MPs, AV+ and tissue factor-bearing (TF+) MPs were measured using flow cytometry. Baseline levels of GFAP+/TF-, TF+/GFAP-, and GFAP+/TF+ MPs were significantly higher in GBM patients than in healthy controls, and significantly increased at each time point after surgery; at 7 months, a further significant increase over the level found a week after surgery was only seen in the subtotally resected patients. The number AV+/CD62E- MPs increased in GBM patients and correlated with MP activity. TF+/GFAP- MPs numbers were significantly higher in 11 GBM patients who developed VTE than in those who did not (p 0.04). TF+/GFAP- MPs levels above the 90th percentile (calculated in GBM patients without VTE) were associated with a higher risk of VTE (RR 4.17, 95% CI 1.57-11.03). In conclusion, the numbers of glial-derived and/or TF-bearing MPs were high in GBM patients both before and even more after the neoplasm was treated, especially in patients with subtotal resection likely according to disease progression. A contribution of TF+/GFAP- MPs to the risk of VTE is suggested.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23803674     DOI: 10.1160/TH12-12-0957

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  22 in total

1.  Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

Authors:  Nadim Tawil; Rayhaan Bassawon; Brian Meehan; Ali Nehme; Laura Montermini; Tenzin Gayden; Nicolas De Jay; Cristiana Spinelli; Shilpa Chennakrishnaiah; Dongsic Choi; Lata Adnani; Michele Zeinieh; Nada Jabado; Claudia L Kleinman; Michael Witcher; Yasser Riazalhosseini; Nigel S Key; David Schiff; Steven P Grover; Nigel Mackman; Charles P Couturier; Kevin Petrecca; Mario L Suvà; Anoop Patel; Itay Tirosh; Hamed Najafabadi; Janusz Rak
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

Review 3.  Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence.

Authors:  Michael W Graner
Journal:  Annu Rev Genomics Hum Genet       Date:  2019-04-12       Impact factor: 8.929

Review 4.  Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.

Authors:  Julia E Geddings; Nigel Mackman
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

5.  Increasing the sensitivity of the human microvesicle tissue factor activity assay.

Authors:  Loris Vallier; Tarik Bouriche; Amandine Bonifay; Coralie Judicone; Jeremy Bez; Corentin Franco; Christophe Guervilly; Yohei Hisada; Nigel Mackman; Reaves Houston; Philippe Poncelet; Françoise Dignat-George; Romaric Lacroix
Journal:  Thromb Res       Date:  2019-07-19       Impact factor: 3.944

Review 6.  Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.

Authors:  Maria Diaz; Jasmin Jo
Journal:  Curr Oncol Rep       Date:  2022-02-18       Impact factor: 5.075

7.  Systemic coagulation is activated in patients with meningioma and glioblastoma.

Authors:  Swaroopa Yerrabothala; Brett L Gourley; James C Ford; Syed Rakin Ahmed; Stephen J Guerin; Marc Porter; Heather A Wishart; Marc S Ernstoff; Camilo E Fadul; Deborah L Ornstein
Journal:  J Neurooncol       Date:  2021-10-15       Impact factor: 4.130

8.  Mutant IDH1 and thrombosis in gliomas.

Authors:  Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2016-09-23       Impact factor: 17.088

9.  Predictors of Venous Thromboembolism in Patients with Glioblastoma.

Authors:  Shahzaib Nabi; Pushpinderdeep Kahlon; Farshid Bozorgnia; Adeel Arshad; Tom Mikkelsen; Vijayalakshmi Donthireddy
Journal:  Pathol Oncol Res       Date:  2015-11-07       Impact factor: 3.201

Review 10.  Cancer-associated pathways and biomarkers of venous thrombosis.

Authors:  Yohei Hisada; Nigel Mackman
Journal:  Blood       Date:  2017-08-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.